CELH
Celsius Holdings, Inc.
CELH has the edge over NUS overall, supported by stronger fundamentals and stronger valuation.
NUS
Nu Skin Enterprises, Inc.
NUS's outlook is improving, though it still trails on the overall score.
CELH Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Strong |
CELH's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
NUS Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Under pressure | |
| Stable |
NUS's balance sheet is currently stable, but its revenue, profitability and cash flow are under pressure.
CELH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 21x | $31.89 | — |
| Current | 35x | $31.89 | — |
| Cheap | 40x | $35.95 | +13% |
| Fair | 141x | $127 | +299% |
| Expensive | 650x | $585 | +1735% |
Historical ranges are pointers, not guarantees.
CELH's PE is in its cheap range at 35x. If earnings grow as analysts expect, today's price would be 21x next year's earnings.
NUS PE Valuation
NUS has no meaningful PE right now: it lost money over the past year.
CELH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| Low |
CELH has the edge over NUS on the outlook, with more favorable revenue expectations.
NUS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Stable | |
| Improving | |
| Limited | |
| High |
Analysts expect NUS's earnings to grow and its profitability to improve, with its revenue holding steady.
CELH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.53 | +70% |
| Q3 2026 | $0.90 | +718% |
| Q2 2026 | $0.24 | -37% |
| Q1 2026 | $0.43 | +30% |
| Q4 2025 | $0.25 | -44% |
| Q3 2025 | $0.11 | -85% |
| Q2 2025 | $0.38 | -62% |
| Q1 2025 | $0.33 | -64% |
| Q4 2024 | $0.45 | -42% |
CELH has the edge over NUS on earnings quality, reporting a profit while its opponent remains loss making.
NUS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.08 | — |
| Q3 2026 | -$4.85 | -322% |
| Q2 2026 | -$4.49 | -323% |
| Q1 2026 | $1.08 | +$1.88 |
| Q4 2025 | $3.18 | +$6.13 |
| Q3 2025 | $2.18 | +$4.26 |
| Q2 2025 | $2.01 | +$5.00 |
| Q1 2025 | -$0.80 | -$0.73 |
| Q4 2024 | -$2.95 | -1835% |
NUS has swung to a loss: it lost $4.85 per share over the past year, after a profit the year before.
CELH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $847.2M | +17% |
| Q2 2026 | $817.9M | +11% |
| Q1 2026 | $782.6M | +138% |
| Q4 2025 | $721.6M | +117% |
| Q3 2025 | $725.1M | +173% |
| Q2 2025 | $739.3M | +84% |
| Q1 2025 | $329.3M | -7.4% |
| Q4 2024 | $332.2M | -4.4% |
CELH has the edge over NUS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | +31 points |
| Q2 2026 | 9.2% | -10 points |
| Q1 2026 | 18% | +2 points |
| Q4 2025 | 3.6% | +9.2 points |
| Q3 2025 | -11% | -9.8 points |
| Q2 2025 | 19% | -4.1 points |
| Q1 2025 | 16% | -7.6 points |
| Q4 2024 | -5.6% | -23 points |
CELH has the edge over NUS on profitability, with a higher operating margin.
NUS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $311M | -15% |
| Q2 2026 | $320.1M | -17% |
| Q1 2026 | $320.6M | -12% |
| Q4 2025 | $370.3M | -17% |
| Q3 2025 | $364.2M | -15% |
| Q2 2025 | $386.1M | -12% |
| Q1 2025 | $364.5M | -13% |
| Q4 2024 | $445.6M | -8.8% |
NUS's revenue has slid since its 2020 peak: $311M last quarter, down 15% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.6% | -4.3 points |
| Q2 2026 | -19% | -27 points |
| Q1 2026 | 1.3% | +4 points |
| Q4 2025 | 6.3% | +18 points |
| Q3 2025 | 5.9% | +1.7 points |
| Q2 2025 | 8% | +37 points |
| Q1 2025 | -2.7% | -4.8 points |
| Q4 2024 | -12% | -15 points |
NUS's operating margin was 1.6% last quarter, down 4.3 points from the same quarter a year ago.
CELH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $127.7M | -60% |
| Q2 2026 | $205.5M | +479% |
| Q1 2026 | $65.8M | -32% |
| Q4 2025 | -$130M | -285% |
| Q3 2025 | $321.5M | +3599% |
| Q2 2025 | $35.5M | +17% |
| Q1 2025 | $96.4M | -26% |
| Q4 2024 | $70.3M | +16394% |
CELH has the edge over NUS on cash generation, producing positive trailing cash flow while its opponent burns cash.
NUS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$19.5M | -211% |
| Q2 2026 | $5M | -86% |
| Q1 2026 | -$17.6M | -$4.4M |
| Q4 2025 | $5.9M | -56% |
| Q3 2025 | $17.6M | -23% |
| Q2 2025 | $35.8M | -17% |
| Q1 2025 | -$13.2M | -$4.2M |
| Q4 2024 | $13.2M | -61% |
NUS's free cash flow has turned negative after years in the green: −$26M over the past year.
CELH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.8% | -2M shares |
| 1 year | -1.1% | -2.9M shares |
| 3 years | +7.4% | +17.6M shares |
| 5 years | +8.3% | +19.5M shares |
| Available history | +32% | +62.4M shares |
CELH has 255M diluted shares, down 1.1% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $300,000 |
| Q2 2026 | $1M |
| Q1 2026 | $8.8M |
| Q4 2025 | $2.5M |
| Q3 2025 | $448,000 |
| Q2 2025 | $879,000 |
| Q1 2025 | $1.9M |
| Q4 2024 | $603,000 |
CELH spent $13M buying back its own shares over the past year, about three times what it spent the year before.
NUS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +81K shares |
| 1 year | -3.2% | -1.6M shares |
| 3 years | -2.4% | -1.2M shares |
| 5 years | -5% | -2.6M shares |
| Available history | -13% | -7.3M shares |
NUS has the edge over CELH on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | $5M |
| Q4 2025 | $10M |
| Q3 2025 | $5M |
| Q2 2025 | — |
| Q1 2025 | $5M |
| Q4 2024 | — |
NUS spent $15M buying back its own shares over the past year, up 50% from the year before.
CELH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.1x | Net Cash |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 0.5x | Very low |
| Q4 2025 | 1.6x | Healthy |
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 1.4x | Healthy |
| Q1 2025 | -7.3x | Net Cash |
| Q4 2024 | -5.5x | Net Cash |
CELH has the edge over NUS on leverage, with a lower net debt burden relative to earnings.
NUS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 0.6x | Very low |
| Q1 2026 | 0.2x | Very low |
| Q4 2025 | -0.1x | Net Cash |
| Q3 2025 | -0.5x | Net Cash |
| Q2 2025 | -0.3x | Net Cash |
| Q1 2024 | 2.4x | Moderate |
| Q4 2023 | 2.1x | Moderate |
NUS's net debt is about 1.6 years of its operating earnings (EBITDA), after holding more cash than debt a year ago.
CELH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 51.3 | Neutral |
| Stochastic | 56.8 | Neutral |
CELH's weekly RSI is 51 (neutral) and its Stochastic is 57 (neutral).
NUS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.1 | Neutral |
| Stochastic | 9.6 | Oversold |
NUS's weekly RSI is 30 (neutral) and its Stochastic is 10 (oversold).
CELH PE vs Consumer Defensive Sector
| Metric | CELH | Sector median | Relative |
|---|---|---|---|
| PE | 35x | 19x | 82% above |
| PE % | 11 | 18 | 7 pts below |
CELH is trading at 35x earnings, a 82% premium to the Consumer Defensive sector's median of 19x.
NUS PE vs Consumer Defensive Sector
| Metric | NUS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 19x | — |
NUS has no meaningful PE right now: it lost money over the past year.
CELH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $29.1 | 9.4% above |
| 20 week MA | $29.6 | 7.8% above |
| 50 week MA | $36.1 | 12% below |
| 100 week MA | $38.8 | 18% below |
| 200 week MA | $44.6 | 29% below |
CELH has the edge over NUS on trend strength, trading above more of its moving averages.
NUS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.58 | 12% below |
| 20 week MA | $4.83 | 17% below |
| 50 week MA | $6.79 | 41% below |
| 100 week MA | $7.68 | 48% below |
| 200 week MA | $14.2 | 72% below |
NUS is in a downtrend: it's below all five of its weekly moving averages, and 72% below its 200-week average.
CELH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.58 | $14.7 | +832% |
| 2021 | $14.7 | $24.9 | +69% |
| 2022 | $24.9 | $35.6 | +43% |
| 2023 | $35.6 | $54.5 | +53% |
| 2024 | $54.5 | $26.5 | -51% |
| 2025 | $26.5 | $45.6 | +72% |
| 2026 YTD | $45.6 | $31.9 | -30% |
CELH has the edge over NUS on returns for 2026, with the stronger performance.
NUS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $40.5 | $54.6 | +35% |
| 2021 | $54.6 | $49.5 | -9.3% |
| 2022 | $49.5 | $41.6 | -16% |
| 2023 | $41.6 | $19.4 | -53% |
| 2024 | $19.4 | $6.76 | -65% |
| 2025 | $6.76 | $9.84 | +46% |
| 2026 YTD | $9.84 | $4.01 | -59% |
NUS has finished lower in four of the last six years. It's down 59% so far in 2026.